Abstract
Objective: The main objective of the present study was to establish and evaluate matrix type transdermal therapeutic systems containing new polymeric combinations (Eudragit E PO/Eudragit RL 100 & Plasdone S 630) as polymers and Labetalol Hydrochloride (LBHCl) as a model drug. Experimental: The matrix type TTS of LBHCl were prepared by film casting technique. The patches were characterized for physical, in vitro release studies and ex-vivo permeation studies using human cadaver skin. On the basis of in vitro drug release study and skin permeation, formulation A1 was found more effective than the other formulations, so it was selected as the optimized formulation. The optimized formulation patch was assessed in detail for its pharmacokinetic, pharmacodynamic, skin irritation potential, and stability studies. Results: The maximum percentage drug release and Permeation in 48 hrs were 92.43 % and 76.24 % respectively for optimized patch. The Korsmeyer peppas release exponent value of 0.604 in the optimized formulation was highly suggestive of release mechanism towards first order release. The observations obtained from the in vivo characterization of the optimized patch were indicative of sustained action of the developed formulation. The interaction studies analysis indicated no chemical interaction among the drug and polymers. The optimized patch appeared free from potentially hazardous skin irritation as observed by skin irritation score of 0.915 < 2.00 (under Draize score test). The optimized formulation was found to be stable at ambient storage conditions. Conclusion: The above TTS holds promise for improved bioavailability and better management of hypertension in long term basis.
Keywords: Matrix type, transdermal, human cadaver skin, labetalol hydrochloride, eudragit E PO, eudragit RL 100, plasdone S -630 (copovidone)
Current Drug Delivery
Title: In Vitro and In Vivo Assessment of Matrix Type Transdermal Therapeutic System of Labetalol Hydrochloride
Volume: 6 Issue: 5
Author(s): Ashu Mittal, Shikha Parmar and Brijendra Singh
Affiliation:
Keywords: Matrix type, transdermal, human cadaver skin, labetalol hydrochloride, eudragit E PO, eudragit RL 100, plasdone S -630 (copovidone)
Abstract: Objective: The main objective of the present study was to establish and evaluate matrix type transdermal therapeutic systems containing new polymeric combinations (Eudragit E PO/Eudragit RL 100 & Plasdone S 630) as polymers and Labetalol Hydrochloride (LBHCl) as a model drug. Experimental: The matrix type TTS of LBHCl were prepared by film casting technique. The patches were characterized for physical, in vitro release studies and ex-vivo permeation studies using human cadaver skin. On the basis of in vitro drug release study and skin permeation, formulation A1 was found more effective than the other formulations, so it was selected as the optimized formulation. The optimized formulation patch was assessed in detail for its pharmacokinetic, pharmacodynamic, skin irritation potential, and stability studies. Results: The maximum percentage drug release and Permeation in 48 hrs were 92.43 % and 76.24 % respectively for optimized patch. The Korsmeyer peppas release exponent value of 0.604 in the optimized formulation was highly suggestive of release mechanism towards first order release. The observations obtained from the in vivo characterization of the optimized patch were indicative of sustained action of the developed formulation. The interaction studies analysis indicated no chemical interaction among the drug and polymers. The optimized patch appeared free from potentially hazardous skin irritation as observed by skin irritation score of 0.915 < 2.00 (under Draize score test). The optimized formulation was found to be stable at ambient storage conditions. Conclusion: The above TTS holds promise for improved bioavailability and better management of hypertension in long term basis.
Export Options
About this article
Cite this article as:
Mittal Ashu, Parmar Shikha and Singh Brijendra, In Vitro and In Vivo Assessment of Matrix Type Transdermal Therapeutic System of Labetalol Hydrochloride, Current Drug Delivery 2009; 6 (5) . https://dx.doi.org/10.2174/156720109789941614
DOI https://dx.doi.org/10.2174/156720109789941614 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Is Nitric Oxide Assuming a Janus-Face in The Central Nervous System?
Current Medicinal Chemistry Mechanisms of Herb-Induced Nephrotoxicity
Current Medicinal Chemistry Neuroinflammation as a Common Mechanism Associated with the Modifiable Risk Factors for Alzheimer’s and Parkinson’s Diseases
Current Aging Science Oxidative-Nitrosative Stress In Hypertension
Current Vascular Pharmacology Therapeutic Approach of Histamine H3 Receptors in Obesity
Recent Patents on CNS Drug Discovery (Discontinued) Atherosclerosis, Degenerative Aortic Stenosis and Statins
Current Drug Targets Protective Effect of α-ketobutyrate on Survival of Hippocampal Neurons Challenged with Hydrogen Peroxide Chemistry Mimicking Brain Ischemia
Current Pharmaceutical Analysis Serum Uric Acid and Risk of Coronary Heart Disease
Current Pharmaceutical Design Pharmacoproteomics in Cardiac Hypertrophy and Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Postprandial Lipemia in Children and Adolescents
Current Vascular Pharmacology Renal Effects of Non-Steroidal Anti-Inflammatory Drugs and Selective Cyclooxygenase-2 Inhibitors
Current Pharmaceutical Design Prediction of miRNA in Human MHC that Encodes Different Immunological Functions Using Support Vector Machines
Current Bioinformatics Endoplasmic Reticulum Stress, Diabetes Mellitus, and Tissue Injury
Current Protein & Peptide Science Ellagic Acid Increases Osteocalcin and Alkaline Phosphatase After Tooth Extraction in Nicotinic-Treated Rats
Current Pharmaceutical Design Vascular Adenosine Receptors; Potential Clinical Applications
Current Vascular Pharmacology Localisation of Endothelin-1 and its Receptors in Vascular Tissue as Seen at the Electron Microscopic Level
Current Vascular Pharmacology The Mediterranean and other Dietary Patterns in Secondary Cardiovascular Disease Prevention: A Review
Current Vascular Pharmacology Vascular Risk Factors and Alzheimer’s Disease Pathogenesis: Are Conventional Pharmacological Approaches Protective For Cognitive Decline Progression?
CNS & Neurological Disorders - Drug Targets Conformation and Bioactivity. Design and Discovery of Novel Antihypertensive Drugs
Current Topics in Medicinal Chemistry Peripartum Cardiomyopathy: Current State of Knowledge, New Developments and Future Directions
Current Cardiology Reviews